Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole
- PMID: 21063463
- PMCID: PMC2963162
- DOI: 10.2147/TCRM.S14425
Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole
Abstract
Objective: To review the literature on the treatment of gastroesophageal reflux disease (GERD) with emphasis on proton pump inhibitors (PPIs), particularly on delayed-release esomeprazole, and to identify properties and adverse effects of PPIs observed in the treatment of GERD in children and adolescents.
Sources: Electronic search of PubMed/Medline and Cochrane Collaboration databases, and of abstracts on DDW, NASPGHAN, and ESPGHAN. We focused on controlled and randomized studies published since 2000 and identified reviews that presented a consensual position, and directives published within the last 10 years.
Main results: PPIs are considered better antisecretory agents than H(2)-receptor antagonists. Although all PPIs are similar, they are not identical in their pharmacologic properties. For example, the acid-suppressive effect of esomeprazole, the S-isomer of omeprazole, persists for more than 16 hours after administration of the morning dose. Therefore, it can control acidity after night meals better than a single dose of omeprazole. Moreover, the onset of the suppressive effect of esomeprazole is faster. It achieves acid inhibition faster than other PPIs.
Conclusion: Currently, the mainstream treatment for GERD in children is a PPI. Although PPIs are safe drugs, effective in healing erosive esophagitis, and in relieving symptoms, studies with esomeprazole have shown that this drug has as powerful an ability to inhibit acid secretion as omeprazole. It also seems that some pharmacologic properties of esomeprazole are actually better for the treatment of GERD.
Keywords: adolescent; child; gastroesophageal reflux; therapy.
Similar articles
-
The use of proton pump inhibitors in children: a comprehensive review.Paediatr Drugs. 2003;5(1):25-40. doi: 10.2165/00128072-200305010-00003. Paediatr Drugs. 2003. PMID: 12513104 Review.
-
A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD).Ther Clin Risk Manag. 2007 Aug;3(4):653-63. Ther Clin Risk Manag. 2007. PMID: 18472988 Free PMC article.
-
[New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].Presse Med. 2004 Jun 19;33(11):746-54. doi: 10.1016/s0755-4982(04)98731-3. Presse Med. 2004. PMID: 15257232 Review. French.
-
Esomeprazole: a clinical review.Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9. doi: 10.1093/ajhp/59.14.1333. Am J Health Syst Pharm. 2002. PMID: 12132559 Review.
-
Pharmacologic management of gastroesophageal reflux disease.Curr Gastroenterol Rep. 2002 Jun;4(3):218-24. doi: 10.1007/s11894-002-0066-3. Curr Gastroenterol Rep. 2002. PMID: 12010622 Review.
Cited by
-
Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.Dig Dis Sci. 2017 Nov;62(11):3059-3068. doi: 10.1007/s10620-017-4743-3. Epub 2017 Sep 15. Dig Dis Sci. 2017. PMID: 28916953 Free PMC article. Clinical Trial.
-
Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents.Dig Dis Sci. 2019 Feb;64(2):493-502. doi: 10.1007/s10620-018-5325-8. Epub 2018 Nov 2. Dig Dis Sci. 2019. PMID: 30390234 Free PMC article. Clinical Trial.
References
-
- Sherman PM, Hassall E, Fagundes-Neto U, et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol. 2009;104:1278–1295. - PubMed
-
- Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) J Pediatr Gastroenterol Nutr. 2009;49:498–547. - PubMed
-
- Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–1920. - PubMed
-
- Gunasekaran TS, Dahlberg M, Ramesh P, Namachivayam G. Prevalence and associated features of gastroesophageal reflux symptoms in a Caucasian-predominant adolescent school population. Dig Dis Sci. 2008;53:2373–2379. - PubMed
-
- Moore DJ, Tao BS, Lines DR, Hirte C, Heddle ML, Davidson GP. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr. 2003;143:219–223. - PubMed
LinkOut - more resources
Full Text Sources